Although predictive tools to identify those at risk of disease progression are in their infancy, the development of such tools is crucial for improving patient outcomes.
The consensus of the advisory committee is that we have significant concerns about the very prolonged delay and getting these confirmatory studies underway.
Scientists are seeing positive early results from treating relapsed/refractory T-cell blood cancers with un–gene-edited chimeric antigen receptor (CAR) T-cell therapy.